Literature DB >> 34314939

LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages.

Zeyu Xing1, Menglu Zhang1, Jiaqi Liu1, Gang Liu1, Kexin Feng1, Xiang Wang2.   

Abstract

BACKGROUND: M2 tumor-associated macrophages are closely related to the progression and prognosis of breast cancer (BCa), and could be regulated by long intergenic non-coding RNAs (lincRNAs). Moreover, the differential expression of lincRNAs affects tumor resistance. This study focused on the potential involvement and mechanism of LINC00337 in BCa.
METHODS: The expression of LINC00337 in BCa was detected by bioinformatics analysis and RT-qPCR. Cell viability and proliferation were analyzed by cell counting kit-8 (CCK-8) and clone formation assay. BCa cells were treated with different concentrations of paclitaxel (PAX) to determine the chemotherapy resistance of LINC00337. Tumor formation assay, Western blot, ELISA and immunohistochemistry were performed to determine the relationship between LINC00337 and PAX in vivo. Macrophages were induced to M2-like polarization, and then functional experiments (CCK-8, wound healing) and molecular experiments (ELISA, RT-qPCR, Western blot) were used to verify the role of LINC00337.
RESULTS: LINC00337 was up-regulated in BCa. High-expressed LINC00337 accelerated viability and proliferation of BCa cells, improved the resistance of BCa cells to PAX, and accelerated tumor growth. Overexpressed LINC00337 up-regulated the expressions of M2 macrophage markers and M-CSF, and reduced the level of GM-CSF. PAX significantly reduced the viability of BCa cells and down-regulated LINC00337. Furthermore, the successfully induced M2 type macrophages to promote BCa cell activity, migration and EMT protein expression, and LINC00337 enhanced the effect of M2 type macrophages. ShLINC00337 had the opposite effect to overexpressed LINC00337.
CONCLUSION: LINC00337 accelerated the malignant phenotype of BCa cells and promoted chemoresistance to paclitaxel through M2-like macrophages.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; LINC00337; Macrophages; Paclitaxel

Year:  2021        PMID: 34314939     DOI: 10.1016/j.molimm.2021.07.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

Review 1.  Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.

Authors:  Maoyu Xiao; Jun He; Liyang Yin; Xiguan Chen; Xuyu Zu; Yingying Shen
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

Review 2.  Non-Coding RNAs in the Crosstalk between Breast Cancer Cells and Tumor-Associated Macrophages.

Authors:  Anna Benedetti; Chiara Turco; Giulia Fontemaggi; Francesco Fazi
Journal:  Noncoding RNA       Date:  2022-02-06

3.  Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.

Authors:  Shengqiang Fu; Binbin Gong; Siyuan Wang; Qiang Chen; Yifu Liu; Changshui Zhuang; Zhilong Li; Zhicheng Zhang; Ming Ma; Ting Sun
Journal:  Int J Gen Med       Date:  2021-11-11

Review 4.  Regulatory Mechanism of lncRNAs in M1/M2 Macrophages Polarization in the Diseases of Different Etiology.

Authors:  Ping Jiang; Xiaopeng Li
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

5.  lncRNA/miR-29c-Mediated High Expression of LOX Can Influence the Immune Status and Chemosensitivity and Can Forecast the Poor Prognosis of Gastric Cancer.

Authors:  Aitao Nai; Huihui Zeng; Qiong Wu; Zirui He; Shuwen Zeng; Shoaib Bashir; Feng Ma; Jie He; Wei Wan; Meng Xu
Journal:  Front Cell Dev Biol       Date:  2022-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.